Navigation Links
Selective inhibition of BMK1 suppresses tumor growth
Date:9/13/2010

A study describing a newly developed pharmacological inhibitor is providing detailed insight into how an enzyme that has been implicated in multiple human malignancies regulates a known tumor suppressor. The research, published by Cell Press in the September 14th issue of the journal Cancer Cell, may have broad application for treating human cancers.

Mitogen-activated protein kinases (MAPKs) are enzymes that regulate multiple cellular activities, including proliferation and cell survival. Mutations in MAPK signaling pathways have been shown to play a significant role in many types of cancer. Of the four different MAPKs that have been identified in mammalian cells, ERK1/2 and BMK1 exhibit significant structural similarity. In fact, recent research has shown that some pharmacological compounds which have been considered to be specific inhibitors of ERK1/2, also interfere with the lesser known BMK1.

"It is critical that results using the common MAPK inhibitors be reevaluated using more specific inhibitors of the BMK1 and ERK1/2 cascades. However, so far there has been no specific small-molecule inhibitor of BMK1 that is effective both in cells and animals," explains senior study author, Dr. Jiing-Dwan Lee, from The Scripps Research Institute in La Jolla, California. "More importantly, the lack of this kind of BMK1 inhibitor has hampered the understanding of the physiological/pathological roles of BMK1."

Dr. Lee and colleagues discovered that promyelocytic leukemia protein (PML), which is a known tumor suppressor, is inhibited by BMK1. "Previous reports had implicated ERK1/2 in the regulation of PML," says Dr. Lee. "However, in our study we found that that BMK1 interacts with PML and suppresses its antitumor actions." To further investigate the BMK1-PML interaction, the researchers developed a compound called XMD8-92 that was remarkably selective at inhibiting BMK1.

Treatment with XMD8-92 blocked tumor cell proliferation and significantly inhibited tumor growth in mice. Importantly XMD8-92 had no obvious negative effects on the animals. "These results demonstrate that the BMK1 pathway can be blocked effectively by a small-molecule inhibitor without apparent adverse effects and, more importantly, BMK1 inhibition is a very effective way to prevent cancer development in animals," concludes Dr. Lee. "As BMK1 is expressed in most tumor cells, our results suggest that cancer therapies targeting BMK1 may be useful for treating diverse types of human tumors."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
2. Bone drug suppresses wandering tumor cells in breast cancer patients
3. Exosomal release of beta-catenin may explain why CD82 and CD9 suppress tumor metastasis
4. In-depth investigation on the capacity of 4-HPR to induce death of tumor cells
5. Tumor budding identified as predictor for unfavorable outcome in lung cancer
6. Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
7. With muscle-building treatment, mice live longer even as tumors grow
8. Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor
9. A lethal brain tumors strength may be a weakness as well
10. Merlin protein found to control liver stem cells, prevent tumor development
11. New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... As President Trump challenges the status quo ... administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, for ... make it through Congress. His discussion will focus on the current state of ...
(Date:4/25/2017)... NV (PRWEB) , ... April 25, 2017 , ... ... now choose a modern procedure that achieves results in a fraction of the ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS Healthcare Solutions ... (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. , BYOD ... devices with a pre-programmed tablet in a remarkably easy-to-use kit for patients. “BYOD ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: